3M COMPANY (MMM): what the price requires

At today's price, 3M COMPANY (MMM) is priced for -3.3% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/MMM

Headline

FieldValue
TickerMMM
Company3M COMPANY
Current price$157.60/sh
CompositionAbrasives 5% / Automotive Aftermarket 5% / Electrical Markets 6% / Industrial Adhesives and Tapes 9% / Industrial Specialties Division 5% / Personal Safety 14% / Roofing Granules 2% / Advanced Materials 3% / Automotive and Aerospace 8% / Commercial Branding and Transportation 10% / Electronics 12% / Consumer Safety and Well-Being 4% / Home and Auto Care 5% / Home Improvement 6% / Packaging and Expression 5% / Corporate and Other 1%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basissegment
Implied growth-3.3%

Solve inputs: computed at a 9.1% cost of capital with 5% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~6pp.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
cohort percentile (of 112 peers)14
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset2.22x4expensive
Earnings7.76x4expensive
Relative1.22x3expensive
Growth1.36x3expensive

Families that justify the price: Relative Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.2%); the inversion above states its own rate.

Per-Model Detail (n=14)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$40.923.85xyesFCF base $2.1B, growth 2% (input: historical growth), terminal g 2.1%, WACC 8.2%, 5yr projection
DCF Exit MultipleGrowth$131.421.20xyesExit EV/EBITDA: 17.0x / 19.0x / 21.0x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$128.431.23xyesP/E 24x (static sector reference · 2026-04), scenarios: 20.3x / 24.0x / 27.7x (bear / base = reference held flat / bull), EV/EBITDA 16x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$56.552.79xyesBV/sh $6.12, ROE (TTM) 85.4%, ke 9.3%
Two-Stage Excess ReturnAsset$307.980.51xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$115.521.36xyesRev $25.0B, growth 2% (input: historical growth; tapered), Terminal P/S: 2.8x / 3.4x / 3.9x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelative——no—
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$24.876.34xyesNormalized EBIT (5y avg op income, one-time charges added back) $2.80B × (1−25%) / WACC 8.2% → EPV (no growth)
Residual IncomeAsset$94.811.66xyesBV $6.12 + 5yr PV of (ROE (TTM) 85.4% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$26.745.89xyes√(22.5 × EPS $5.19 × BVPS $6.12) — Graham's conservative floor
EV/EBITDA RelativeRelative$128.691.22xyesEBITDA $5.11B × sector EV/EBITDA 16.0x
FCF YieldEarnings$17.169.18xyesFCF $2060.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$12.6912.42xyesSBC-adj FCF $1.84B (FCF $2.06B − SBC $0.22B) capitalized at Kₑ
Ben Graham FormulaEarnings$4.3536.23xyesEPS $5.19 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset$4.7832.97xyesBV $6.12 × (ROIC 6.4% / WACC 8.2%) (excluded from median)
P/Sales SectorRelative$187.870.84xyesRevenue $25.02B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings$56.112.81xyesEPS $5.19 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$13.9b
Net debt / NOPAT (after-tax)3.55x
Net debt / operating income (pre-tax)2.65x
Interest coverage11.7x
Share count CAGR (buyback)-6.2%
Burning cashno

Bullet Takeaways

Bull Case

What the standard valuation lenses miss about 3M is that its reported numbers are in the middle of a cleanup, and the cleanup is going better than the headline admits. GAAP earnings per share fell 40% in the first quarter to $1.23, but that drop came from the declining value of the company's retained stake in Solventum, the healthcare business it spun off, and from costs of exiting its PFAS chemistry, neither of which reflects the operating business. Strip those out and adjusted EPS was $2.14, ahead of the $2.00 estimate. A buyer who anchors on the GAAP number sees a company in decline; a buyer who looks at the operating line sees one expanding margins.

The turnaround has real evidence behind it now. First-quarter operating margin reached 23.2%, up 230 basis points year over year, on a focus the company describes as simplifying and standardizing its processes, footprint, and portfolio. That is the textbook self-help lever: a sprawling conglomerate that had grown complex is cutting cost and complexity, and margin expansion of that size on flat-ish revenue drops straight to earnings. Management reiterated full-year guidance of $8.50 to $8.70 adjusted EPS with 70 to 80 basis points of further margin improvement, signaling confidence that the operational gains continue.

The franchise underneath remains genuinely valuable. 3M is a research-and-development house at its core, and the breadth of the portfolio, abrasives, adhesives, tapes, personal safety, electronics materials, is a collection of niche businesses where 3M often holds a technical edge and pricing power. The company pays a meaningful dividend, near a 2% yield, and has been buying back stock, with the share count falling. The bull case is that the litigation overhang and the Solventum-stake noise are masking a focused, higher-margin industrial that the market is valuing on its messy GAAP optics rather than its improving operating reality, and that as the legal liabilities crystallize into known numbers, the discount narrows.

Bear Case

The methods disagree on 3M almost as sharply as they can, and the disagreement is the bear's argument. Only the peer-multiple lens reaches the price; the asset-value and earnings-power methods land far below it. The conservative reading is usually the more honest one, and here it is doubly so, because the optimistic case depends on adjusting away exactly the items, the Solventum-stake decline and the PFAS exit costs, that a skeptical investor would say ARE the business. A company that requires its worst expenses to be labeled non-recurring, year after year, is asking the investor to trust an adjusted number over a reported one, and the gap between $2.14 of adjusted EPS and $1.23 of GAAP EPS is precisely where that trust is tested.

The growth is also weak, which undercuts the premium the relative-multiple lens implies. Adjusted organic sales growth decelerated to about 1.2% in the quarter, with the United States flat at 0.0% and only China accelerating. A turnaround built on margin expansion can run for a while on cost-cutting, but cost-cutting has a floor; eventually the company needs the top line to grow, and a sub-2% organic rate is barely keeping pace with inflation. The price embeds an assumption that the premium segment roughly holds flat, which is undemanding, but it also leaves little room for the revenue to actually shrink, which it could if the industrial cycle softens.

The litigation and environmental overhang is the structural risk no operating improvement can fully retire. The 10-K describes potential "restrictions on or added costs for business operations going forward, including in the form of restrictions on discharges at manufacturing facilities, requiring the installation of control technologies, suspension or shutdown of" operations tied to its chemistry exposure. Settlements of this kind are paid over many years, the ultimate cost is uncertain, and the cash that funds them is cash not returned to shareholders. Net debt of roughly $13.9 billion sits at about three times operating income, manageable but real, and a leveraged company with open-ended legal liabilities has a balance sheet that is more fragile than the headline coverage ratio suggests. The bear case is that the adjusted earnings flatter a slow-growing business, the GAAP earnings reflect liabilities that are genuinely 3M's, and the price on a peer multiple credits a clean industrial that the litigation overhang says it is not yet.

Valuation

For a conglomerate this broad, the cleaner read is what the price assumes of the segment carrying the premium, and the answer is modest. The Transportation and Electronics business inverts to roughly flat operating growth, about negative 0.3% a year over five years at today's price, and it sits in the lower half of its peer multiple range. The market is not paying for acceleration; it is paying for stability. That is a reasonable bar for a turnaround, and it frames the whole valuation: 3M does not need to grow fast to justify the price, it needs to stop the bleeding and hold the operating gains.

The methods, however, split unusually wide, and the split is the central fact. Only the peer-multiple lens reaches $160.65 (June 27, 2026); the asset-value and earnings-power lenses land far below. The reason cuts both ways. On the optimistic side, the earnings-power method capitalizes a normalized operating profit that is still weighed down by restructuring and legal noise, so it understates a business now running a 23.2% operating margin. On the skeptical side, those same lenses are reading the GAAP reality, where retained-stake markdowns and PFAS costs are real cash and real value leakage. The honest synthesis is that the stock is priced on the assumption that the adjusted, cleaned-up earnings are the true earnings, and the discount the static methods apply is the market's residual doubt that the cleanup is complete.

Solvency is the constraint that the litigation makes load-bearing. Net debt of about $13.9 billion sits at roughly three times trailing operating income, with interest coverage above five times, which is investment-grade and serviceable. But the legal settlements are paid over years from that same cash flow, and a meaningful share of free cash is committed to liabilities rather than to growth or returns. The dividend remains substantial and the share count is falling, so capital is still being returned, but the ceiling on returns is the open-ended legal bill. The decisive question for the valuation is not the multiple but the trust: whether the adjusted earnings the price relies on prove durable as the restructuring matures, and whether the PFAS and related liabilities settle into a known, bounded number. Until they do, the gap between the methods is not noise; it is the price of the uncertainty.

Catalysts

3M's first-quarter 2026 report showed the turnaround intact but the growth still soft. Adjusted EPS of $2.14 beat the $2.00 estimate, though revenue of $6.0 billion rose just 1.3% and slightly missed, and GAAP EPS of $1.23 fell 40% on the declining value of the retained Solventum stake and PFAS exit costs. The bright spot was margin: operating margin reached 23.2%, up 230 basis points, evidence the cost and complexity reductions are landing. Organic growth, however, decelerated to about 1.2%, with the United States flat and China the lone accelerator.

Management reiterated full-year 2026 guidance of $8.50 to $8.70 adjusted EPS, roughly 4% adjusted sales growth, and 70 to 80 basis points of further margin expansion, which keeps the turnaround narrative on track. The catalysts to watch are the pace of organic growth re-accelerating beyond cost-driven margin gains, continued progress on the portfolio simplification, and above all the trajectory of the PFAS and related legal liabilities, where any clarity on the ultimate cost and timing would directly reduce the discount the market applies. The value of the retained Solventum stake will also keep moving GAAP earnings around, so the adjusted figures remain the better gauge of the underlying business.

Peer Cohorts (Per Segment, With Filing Citations)

Safety and Industrial / Transportation and Electronics (reported)

Consumer (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

3M Q1 2026 results, April 2026 · 3M FY2025 10-K

View the full interactive MMM report on boothcheck